ArticleCurrent oncology (Toronto, Ont.)2025

Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma.

Julie Williamson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.